State of New Jersey Common Pension Fund D Grows Stock Holdings in Sarepta Therapeutics, Inc. $SRPT

State of New Jersey Common Pension Fund D boosted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 59.9% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 48,555 shares of the biotechnology company’s stock after purchasing an additional 18,190 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Sarepta Therapeutics were worth $830,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of SRPT. Cambridge Investment Research Advisors Inc. raised its position in shares of Sarepta Therapeutics by 5.9% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 6,387 shares of the biotechnology company’s stock valued at $408,000 after buying an additional 358 shares in the last quarter. New York State Teachers Retirement System raised its position in Sarepta Therapeutics by 3.3% during the first quarter. New York State Teachers Retirement System now owns 79,361 shares of the biotechnology company’s stock valued at $5,065,000 after purchasing an additional 2,512 shares during the period. GF Fund Management CO. LTD. raised its position in Sarepta Therapeutics by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 2,446 shares of the biotechnology company’s stock valued at $156,000 after purchasing an additional 440 shares during the period. Linden Thomas Advisory Services LLC raised its holdings in Sarepta Therapeutics by 5.6% during the 1st quarter. Linden Thomas Advisory Services LLC now owns 11,809 shares of the biotechnology company’s stock valued at $754,000 after buying an additional 625 shares during the period. Finally, Arcadia Investment Management Corp MI raised its holdings in Sarepta Therapeutics by 12.7% during the 1st quarter. Arcadia Investment Management Corp MI now owns 7,815 shares of the biotechnology company’s stock valued at $499,000 after buying an additional 880 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Up 3.3%

SRPT opened at $24.01 on Monday. The stock’s fifty day moving average is $20.23 and its two-hundred day moving average is $26.75. The company has a market capitalization of $2.35 billion, a P/E ratio of -27.60 and a beta of 0.51. Sarepta Therapeutics, Inc. has a 52 week low of $10.41 and a 52 week high of $138.81. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, beating the consensus estimate of $0.89 by $1.13. The firm had revenue of $611.09 million for the quarter, compared to analyst estimates of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The business’s revenue for the quarter was up 68.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.07 earnings per share. Analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Leerink Partners increased their target price on shares of Sarepta Therapeutics from $12.00 to $15.00 and gave the company a “market perform” rating in a research note on Tuesday, September 9th. JPMorgan Chase & Co. raised shares of Sarepta Therapeutics from an “underweight” rating to a “neutral” rating and set a $24.00 price objective on the stock in a research report on Tuesday, July 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sarepta Therapeutics in a research report on Tuesday, October 14th. Robert W. Baird increased their price target on Sarepta Therapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a report on Thursday, July 17th. Finally, Barclays upgraded Sarepta Therapeutics from an “underweight” rating to an “equal weight” rating and set a $22.00 price target on the stock in a report on Tuesday, July 29th. Eight research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and seven have issued a Sell rating to the company. According to data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Hold” and an average price target of $34.50.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.